Inviting an author to review:
Find an author and click ‘Invite to review selected article’ near their name.
Search for authorsSearch for similar articles
5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Challenges and solutions to system-wide use of precision oncology as the standard of care paradigm

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Abstract

          The personalised oncology paradigm remains challenging to deliver despite technological advances in genomics-based identification of actionable variants combined with the increasing focus of drug development on these specific targets. To ensure we continue to build concerted momentum to improve outcomes across all cancer types, financial, technological and operational barriers need to be addressed. For example, complete integration and certification of the ‘molecular tumour board’ into ‘standard of care’ ensures a unified clinical decision pathway that both counteracts fragmentation and is the cornerstone of evidence-based delivery inside and outside of a research setting. Generally, integrated delivery has been restricted to specific (common) cancer types either within major cancer centres or small regional networks. Here, we focus on solutions in real-world integration of genomics, pathology, surgery, oncological treatments, data from clinical source systems and analysis of whole-body imaging as digital data that can facilitate cost-effectiveness analysis, clinical trial recruitment, and outcome assessment. This urgent imperative for cancer also extends across the early diagnosis and adjuvant treatment interventions, individualised cancer vaccines, immune cell therapies, personalised synthetic lethal therapeutics and cancer screening and prevention. Oncology care systems worldwide require proactive step-changes in solutions that include inter-operative digital working that can solve patient centred challenges to ensure inclusive, quality, sustainable, fair and cost-effective adoption and efficient delivery. Here we highlight workforce, technical, clinical, regulatory and economic challenges that prevent the implementation of precision oncology at scale, and offer a systematic roadmap of integrated solutions for standard of care based on minimal essential digital tools. These include unified decision support tools, quality control, data flows within an ethical and legal data framework, training and certification, monitoring and feedback. Bridging the technical, operational, regulatory and economic gaps demands the joint actions from public and industry stakeholders across national and global boundaries.

          Related collections

          Most cited references83

          • Record: found
          • Abstract: found
          • Article: not found

          Diffusion of innovations in service organizations: systematic review and recommendations.

          This article summarizes an extensive literature review addressing the question, How can we spread and sustain innovations in health service delivery and organization? It considers both content (defining and measuring the diffusion of innovation in organizations) and process (reviewing the literature in a systematic and reproducible way). This article discusses (1) a parsimonious and evidence-based model for considering the diffusion of innovations in health service organizations, (2) clear knowledge gaps where further research should be focused, and (3) a robust and transferable methodology for systematically reviewing health service policy and management. Both the model and the method should be tested more widely in a range of contexts.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019 : A Systematic Analysis for the Global Burden of Disease Study 2019

            Question What was the burden of cancer globally and across Sociodemographic Index (SDI) groupings in 2019, and how has incidence, morbidity, and mortality changed since 2010? Findings In this systematic analysis, there were 23.6 million new global cancer cases in 2019 (17.2 million when excluding those with nonmelanoma skin cancer), 10.0 million cancer deaths, and an estimated 250 million disability-adjusted life years estimated to be due to cancer; since 2010, these represent increases of 26.3%, 20.9%, and 16.0%, respectively. Absolute cancer burden increased in all SDI quintiles since 2010, but the largest percentage increases occurred in the low and low-middle SDI quintiles. Meanings The study results suggest that increased cancer prevention and control efforts are needed to equitably address the evolving and increasing burden of cancer across the SDI spectrum. Importance The Global Burden of Diseases, Injuries, and Risk Factors Study 2019 (GBD 2019) provided systematic estimates of incidence, morbidity, and mortality to inform local and international efforts toward reducing cancer burden. Objective To estimate cancer burden and trends globally for 204 countries and territories and by Sociodemographic Index (SDI) quintiles from 2010 to 2019. Evidence Review The GBD 2019 estimation methods were used to describe cancer incidence, mortality, years lived with disability, years of life lost, and disability-adjusted life years (DALYs) in 2019 and over the past decade. Estimates are also provided by quintiles of the SDI, a composite measure of educational attainment, income per capita, and total fertility rate for those younger than 25 years. Estimates include 95% uncertainty intervals (UIs). Findings In 2019, there were an estimated 23.6 million (95% UI, 22.2-24.9 million) new cancer cases (17.2 million when excluding nonmelanoma skin cancer) and 10.0 million (95% UI, 9.36-10.6 million) cancer deaths globally, with an estimated 250 million (235-264 million) DALYs due to cancer. Since 2010, these represented a 26.3% (95% UI, 20.3%-32.3%) increase in new cases, a 20.9% (95% UI, 14.2%-27.6%) increase in deaths, and a 16.0% (95% UI, 9.3%-22.8%) increase in DALYs. Among 22 groups of diseases and injuries in the GBD 2019 study, cancer was second only to cardiovascular diseases for the number of deaths, years of life lost, and DALYs globally in 2019. Cancer burden differed across SDI quintiles. The proportion of years lived with disability that contributed to DALYs increased with SDI, ranging from 1.4% (1.1%-1.8%) in the low SDI quintile to 5.7% (4.2%-7.1%) in the high SDI quintile. While the high SDI quintile had the highest number of new cases in 2019, the middle SDI quintile had the highest number of cancer deaths and DALYs. From 2010 to 2019, the largest percentage increase in the numbers of cases and deaths occurred in the low and low-middle SDI quintiles. Conclusions and Relevance The results of this systematic analysis suggest that the global burden of cancer is substantial and growing, with burden differing by SDI. These results provide comprehensive and comparable estimates that can potentially inform efforts toward equitable cancer control around the world. The Global Burden of Diseases, Injuries, and Risk Factors Study 2019 examines cancer burden and trends globally for 204 countries and territories and by Socio-demographic Index quintiles from 2010 to 2019.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment.

                Bookmark

                Author and article information

                Journal
                Camb Prism Precis Med
                Camb Prism Precis Med
                PCM
                Cambridge Prisms: Precision Medicine
                Cambridge University Press (Cambridge, UK )
                2752-6143
                2024
                26 March 2024
                : 2
                : e4
                Affiliations
                [1 ]Diagnostics Division, Roche Information Solutions, F. Hoffmann-La Roche Ltd. , Basel, Switzerland
                [2 ]Oxford Molecular Pathology Institute, Sir William Dunn School of Pathology, University of Oxford , Oxford, UK
                [3 ]Nuffield Department of Primary Care Health Sciences, Radcliffe Observatory Quarter , Oxford, UK
                [4 ]Oxford University Hospitals NHS Foundation Trust , Oxford, UK
                [5 ]Roche Healthcare Consulting, Roche Diagnostics Limited , West Sussex, UK
                [6 ]Wales Research and Diagnostic PET Imaging Centre, University Hospital of Wales , Cardiff, UK
                [7 ]Big Data Institute, Li Ka Shing Centre for Health Information and Discovery , Oxford, UK
                Clinical Ethics, Law and Society, Wellcome Trust Centre for Human Genetics , United Kingdom of Great Britain and Northern Ireland
                Institute of Cardiovascular & Medical Sciences, University of Glasgow College of Medical Veterinary and Life Sciences , United Kingdom of Great Britain and Northern Ireland
                Clinical Ethics, Law and Society, Wellcome Trust Centre for Human Genetics , United Kingdom of Great Britain and Northern Ireland
                Institute of Cardiovascular & Medical Sciences, University of Glasgow College of Medical Veterinary and Life Sciences , United Kingdom of Great Britain and Northern Ireland
                Author notes
                Corresponding author: A. B. Hassan; Email: bass.hassan@ 123456path.ox.ac.uk
                Author information
                https://orcid.org/0009-0007-6575-5243
                Article
                S2752614324000012
                10.1017/pcm.2024.1
                11062796
                38699518
                e6967adb-f848-4e5c-b497-2c5e30bc43a9
                © The Author(s) 2024

                This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence ( http://creativecommons.org/licenses/by/4.0), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.

                History
                : 25 October 2023
                : 02 February 2024
                : 12 March 2024
                Page count
                Figures: 2, References: 89, Pages: 10
                Categories
                Review
                Omics
                Genomics
                Data Science
                Digital Health
                Data Science
                Data Integration
                Health Economics
                Efficiency and Cost Reduction

                precision medicine,precision oncology,cost-effectiveness,health data,patient record,interoperability,standard of care,patient centred

                Comments

                Comment on this article

                scite_
                0
                0
                0
                0
                Smart Citations
                0
                0
                0
                0
                Citing PublicationsSupportingMentioningContrasting
                View Citations

                See how this article has been cited at scite.ai

                scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

                Similar content56

                Most referenced authors2,682